Identification by Protein Redirects Clinical Diagnosis of Neurodegenerative Diseases
WASHINGTON, DC—Years of investigation into cellular mechanisms has produced a translational shift in the approach to... More
How Do Stroke and Sleep Apnea Affect Cognition?
WASHINGTON, DC—Patients with stroke and sleep apnea may have worse memory and executive function, compared with... More
Allan Krumholz, MD
Dr. Krumholz, lead author of the AAN/AES guideline on management of first unprovoked seizures, discusses the key points... More
Does Amyloid Accumulation Cause Midlife Cognitive Decline?
Cognitive decline in middle age may not result from β-amyloid deposition, according to a study published online ahead... More
Stroke Survivors May Have Increased Risk of Cancer
NASHVILLE—The annual rate of age-adjusted cancer incidence is higher among patients who have had ischemic stroke,... More

Alzheimer's Association International Conference

WASHINGTON, DC—Solanezumab, an anti-amyloid monoclonal antibody, may have a disease-modifying effect on Alzheimer’s disease, according a delayed-start analysis presented at the 2015 Alzheimer’s Association International Conference. The analysis... More »
 

Alzheimer's Association International Conference

WASHINGTON, DC—Patients over age 60 with type 1 diabetes have an approximately 93% increased risk of dementia, compared with patients who do not have diabetes, according to data described at the 2015 Alzheimer’s Association International Conferen... More »
 

Alzheimer's Association International Conference

WASHINGTON, DC—Metabolomics analyses of saliva samples may discriminate normal aging, mild cognitive impairment (MCI), and Alzheimer’s disease populations, according to research presented at the 2015 Alzheimer’s Association International Confer... More »
 
Successful treatment with antihypertensive medications does not reduce the risk of stroke to the level of a person who is normotensive without medication, according to research published in the June issue of Stroke. Furthermore, stroke risk increases... More »
 

American Academy of Neurology

WASHINGTON, DC—Although treatment algorithms for multiple sclerosis (MS) cannot be adopted formally yet, FDA approval of nearly a dozen therapies in recent years has yielded enough data to support several useful treatment strategies. At the center ... More »
 
Cognitive behavioral therapy for insomnia (CBT-I) is an effective treatment for adults with chronic insomnia, according to a review published online ahead of print June 9 in Annals of Internal Medicine. Researchers analyzed 20 randomized controlled t... More »
 

American Academy of Neurology

WASHINGTON, DC—Measuring transcutaneous carbon dioxide partial pressure (TCpCO²) may identify increased seizure severity and duration, according to research described at the 67th Annual Meeting of the American Academy of Neurology. The technique a... More »
 

American Academy of Neurology

WASHINGTON, DC—Nonmotor symptoms of Parkinson’s disease, including problems with vision, cognition, mood, and sleep, may be targeted with various behavioral and environmental interventions, according to a presentation at the 67th Annual Meeting o... More »
 
Two decades ago, the NINDS study showed that IV t-PA was relatively effective when treating physicians used only a CT scan and a checklist dominated by time and comorbidities to choose recipients of IV t-PA. Later studies showed that the decision to ... More »
 
Brain imaging signs may not indicate an increased risk of symptomatic intracranial hemorrhage after treatment with IV t-PA, according to a study in the May Lancet Neurology. Certain early ischemic and pre-existing signs are associated with reduced in... More »
 
Low muscle strength in late adolescence may indicate the presence of subclinical motor deficits and predict a subsequent diagnosis of Parkinson’s disease, according to data published May 5 in Neurology. “The pattern of reduced muscle strength onl... More »
 

International Headache Congress

VALENCIA, SPAIN—Medication overuse headache (MOH) is strongly associated with high stress levels and several unhealthy but modifiable behaviors, according to a large Danish population-based study. “High stress plus smoking, low physical activity... More »
 

American Academy of Neurology

WASHINGTON, DC—Investigators are examining alpha-synuclein as a target for Parkinson’s disease therapy in various ways, according to a presentation at the at the 67th Annual Meeting of the American Academy of Neurology. “You can block rele... More »
 

American Academy of Neurology

WASHINGTON, DC—A novel threshold tracking transcranial magnetic stimulation (TMS) technique reliably distinguishes between amyotrophic lateral sclerosis (ALS) and non-ALS disorders, according to research presented at the 67th Annual Meeting of the ... More »
 

American Academy of Neurology

WASHINGTON, DC—A new investigational drug for Rett syndrome is well tolerated and may provide clinical benefit, according to a presentation at the 67th Annual Meeting of the American Academy of Neurology. Currently, no therapy is approved for the t... More »
 

American Academy of Neurology

WASHINGTON, DC—The Four-Variable Screening Tool may be a useful method of screening for obstructive sleep apnea within 90 days of stroke, according to study results presented at the 67th Annual Meeting of the American Academy of Neurology. The vari... More »
 

Consortium of Multiple Sclerosis Centers

INDIANAPOLIS—Compared with interferon β-1a, daclizumab high-yield process (DAC HYP) may provide greater improvement in the patient-centered outcomes of ambulation and cognition for patients with relapsing-remitting multiple sclerosis (MS), accordi... More »
 

Consortium of Multiple Sclerosis Centers

INDIANAPOLIS—Most patients with relapsing-remitting multiple sclerosis (MS) remain free of new MRI activity for four years after initiating treatment with alemtuzumab, according to data presented at the 2015 CMSC Annual Meeting. Alemtuzumab also ap... More »
 

Consortium of Multiple Sclerosis Centers

INDIANAPOLIS—A majority of patients remain stable when switching from natalizumab to dimethyl fumarate, according to data presented at the 2015 CMSC Annual Meeting. Factors such as sex, age, and duration of natalizumab treatment may predict the pro... More »
 

Consortium of Multiple Sclerosis Centers

INDIANAPOLIS—Early detection of progressive multifocal leukoencephalopathy (PML) may improve outcomes, according to an update presented at the 2015 CMSC Annual Meeting. When PML results from reversible immunosuppression, as in patients with multipl... More »
 

American Academy of Neurology

WASHINGTON, DC—Familial genetic studies suggest that GLUT1 deficiency may be more common among patients with epilepsy than previously understood, according to Ingrid Scheffer, MBBS, PhD, Professor of Pediatric Neurology at the University of Melbour... More »
 

American Academy of Neurology

WASHINGTON, DC—Among patients with Parkinson’s disease, aerobic exercise may improve white matter integrity in the putamen, according to research presented at the 67th Annual Meeting of the American Academy of Neurology. The increased white matte... More »
 

American Academy of Neurology

WASHINGTON, DC—The motor subtype classification of patients with Parkinson’s disease may shift over time, according to research presented at the 67th Annual Meeting of the American Academy of Neurology. Patients primarily shift from a tremor-domi... More »
 

American Academy of Neurology

WASHINGTON, DC—A drug that contains dextromethorphan and quinidine may reduce agitation in patients with Alzheimer’s disease, according to a study described at the 67th Annual Meeting of the American Academy of Neurology. The drug, known as AVP-9... More »
 

American Academy of Neurology

WASHINGTON, DC—Patients taking perampanel may not require routine laboratory monitoring, according to data from three trials presented at the 67th Annual Meeting of the American Academy of Neurology. Those taking the adjunctive seizure treatment sh... More »
 
The concept that biotin, a water-soluble vitamin, could have a beneficial effect on the course of multiple sclerosis (MS) is biologically plausible. Biotin activates acetyl-CoA carboxylase, a potential rate-limiting enzyme in myelin synthesis, and ha... More »
 

International Congress of Parkinson’s Disease and Movement Disorders

At the 19th International Congress of Parkinson's Disease and Movement Disorders, Dr. LeWitt describes new levodopa preparations in development.... More »
 

International Congress of Parkinson’s Disease and Movement Disorders

Dr. Duda discusses risk factors for Parkinson's disease that are associated with military service.... More »
 

American Headache Society

Dr. Buse discusses an analysis of actual dialogues between general neurologists and patients with chronic migraine during routine office visits and offers suggestions for improving physician–patient communication.... More »
 

American Headache Society

At the 57th Annual Meeting of the American Headache Society, Dr. Bond discusses clinical pain catastrophizing in women with migraine and obesity.... More »
 

American Headache Society

Dr. Bigal discusses the findings from two phase IIb clinical trials of TEV-48125, a CGRP monoclonal antibody, for the preventive treatment of chronic migraine and for high-frequency episodic migraine.... More »
 
Dr. Thadani discusses the range of neuromodulation strategies available for the treatment of seizures, proper patient selection, and treatment outcomes. ... More »
 
An open-label study indicates that patients with multiple sclerosis may benefit from switching to alemtuzumab.... More »
 
Dr. Ardeshna discusses the unique challenges posed by epilepsy in the rapidly expanding elderly population. ... More »
 
Does amyloid accumulation cause the cognitive decline observed in middle age?... More »
 
An investigator on the ESCAPE trial examines the current evidence for endovascular therapy in acute ischemic stroke.... More »
 

JULY 2015

This supplement highlights the on-site reporting prepared by the editorial staff of Neurology Reviews.... More »
 

MARCH 2015

This supplement is sponsored by Raptor Pharmaceuticals Inc.... More »